However, the glut of genomic and epigenomic aberrations accrued during progression continue to converge on characteristic ‘prostate cancer pathways’ with scant regard to molecular subtype: ultimately leading to a highly heterogeneous transcriptomic landscape, centered on an overactive androgen receptor (AR) signaling axis. Here, AR is linked to prostate cancer.